Solventum Corporation (SOLV)
| Market Cap | 12.93B |
| Revenue (ttm) | 8.25B |
| Net Income (ttm) | 479.00M |
| Shares Out | 173.00M |
| EPS (ttm) | 2.76 |
| PE Ratio | 27.08 |
| Forward PE | 13.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,697,365 |
| Open | 75.09 |
| Previous Close | 75.51 |
| Day's Range | 74.52 - 75.40 |
| 52-Week Range | 47.16 - 85.92 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 79.86 (+6.84%) |
| Earnings Date | Apr 7, 2025 |
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wr... [Read more]
Financial Performance
In 2024, Solventum's revenue was $8.25 billion, an increase of 0.70% compared to the previous year's $8.20 billion. Earnings were $479.00 million, a decrease of -64.41%.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SOLV stock is "Hold." The 12-month stock price forecast is $79.86, which is an increase of 6.84% from the latest price.
News
Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations
In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental o...
3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy
On Thursday, Solventum SOLV hosted its 2025 Investor Day, during which it outlined its strategic priorities, its business segments, and its long-range plan (LRP) to drive growth and value creation.
Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
Provides 2028 Targets for Revenue Growth, Margin Expansion, and Free Cash Flow ST. PAUL, Minn.
Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance
ST. PAUL, Minn. , March 12, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic ...
Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations and External Finance Com...
Solventum forecasts annual profit above estimates on strong surgical product sales
3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41 Generated $219 million in cash from operations; fre...
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
Learn more about Solventum's long-term strategy to accelerate growth Join in person or via virtual webcast ST. PAUL, Minn.
Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal repor...
Trian Comments on Solventum's Sale of its Purification & Filtration Business
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company's...
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion
Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for...
Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive agreem...
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today ann...
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
ST. PAUL, Minn. , Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1...
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
Company to host an Investor Day in March 2025 ST. PAUL, Minn.
Peltz's Trian Fund says 3M's Solventum spin-off not living up to potential
Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential.
Trian Issues Open Letter to Solventum Shareholders
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the org...
Solventum to Participate in the Piper Sandler Healthcare Conference
ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on ...
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment
Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn.
Solventum Corporation (SOLV) Q3 2024 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Parti...
Solventum raises annual profit forecast on strong surgical product sales
3M spin-off Solventum raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3% GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64 Generated $169 million in cash from operations; free cash f...